Trial Profile
Phase Ib Study to Evaluate the Safety and Efficacy of TQB2450 (PD-L1 Antibody) Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 07 Jun 2022 Results (by 8 Dec 2021, n=19) assessing the safety and efficacy of the combination therapy of TQB2450 in patients with advanced acral melanoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 29 Oct 2019 Status changed from not yet recruiting to recruiting.
- 20 Jun 2019 New trial record